子宫颈癌诊断市场规模 - 按诊断方法、年龄层、最终用途和预测，2024-2032 年

由于人们越来越意识到子宫颈癌早期检测和筛检计画的重要性，预计从 2024 年到 2032 年，子宫颈癌诊断市场规模将以超过 5.3% 的CAGR扩大。 HPV 检测和液基细胞学等诊断技术的持续发展正在提高子宫颈癌诊断的准确性和效率。

全球子宫颈癌发生率不断上升，特别是在发展中地区，增加了对诊断的需求。根据美国癌症协会预测，到 2024 年，美国将诊断出 13,820 例新的侵袭性子宫颈癌病例。多个政府也正在发起倡议和医疗保健活动，以促进子宫颈癌筛检和预防。

2023 年 9 月，国际癌症研究机构 (IARC) 及其合作伙伴的科学家启动了 EASTER 项目，旨在验证子宫颈癌筛检和诊断的新技术。此类开发子宫颈癌诊断新技术的项目的启动将为市场发展提供动力。

子宫颈癌诊断产业分为诊断方法、年龄层、最终用途和地区。

根据诊断方法，由于子宫颈癌诊断的广泛采用，HPV DNA 检测的市场价值预计到 2032 年将以 5.6% 的CAGR增长。这些检测在检测人类乳突病毒 (HPV) 感染（子宫颈癌的主要原因）方面具有高灵敏度和特异性。 HPV DNA 检测还可以进行早期检测和干预，以改善患者的治疗结果，进一步推动全球子宫颈癌筛检计画的使用率不断提高。

就最终用途而言，诊断影像中心预计将在子宫颈癌诊断市场中累积相当大的份额，2024年至2032年的CAGR为4.9%。这是由于人们越来越认识到定期子宫颈癌筛检的重要性。最近，专门中心已经高度可用先进的诊断影像技术。这些中心提供子宫颈癌检测的专业服务，透过阴道镜、MRI 和超音波等技术提供准确、及时的诊断，有助于改善患者的治疗效果。

从地区来看，由于医疗保健支出不断增加、宣传活动不断加强以及政府改善女性健康倡议的推出，亚太地区子宫颈癌诊断市场规模从 2024 年到 2032 年将以 5.6% 的速度增长。中国和印度等新兴经济体医疗基础设施的快速发展，以及筛检计画的日益普及，将推动区域产业的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球子宫颈癌盛行率上升
    • 政府和其他组织为传播疾病意识而采取的多项倡议
    • HPV 感染发生率上升
    • 诊断技术的进步
  • 产业陷阱与挑战
    • 获得医疗服务的机会有限
    • 社会耻辱与文化障碍
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 战略仪表板

第 5 章：市场估计与预测：透过诊断方法，2018 - 2032

• 主要趋势
• 子宫颈抹片检查
• HPV DNA 检测
• 阴道镜检查
• 活检和子宫颈内刮除术
• 其他诊断方法

第 6 章：市场估计与预测：按年龄划分，2018 - 2032

• 主要趋势
• 20-40岁
• 40岁以上

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 诊断实验室
• 诊断影像中心
• 癌症研究机构
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Arbor Vita Corporation
• Becton, Dickinson and Company (BD)
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Fujirebio Diagnostics, Inc.
• Hologic, Inc.
• QIAGEN
• Seegene Inc
• Thermo Fisher Scientific Inc.

Cervical Cancer Diagnostics Market size is estimated to expand at over 5.3% CAGR from 2024 to 2032, on account of the increasing awareness about the importance of early detection and screening programs for cervical cancer. Rising developments in diagnostic techniques like HPV testing and liquid-based cytology are improving the accuracy and efficiency of cervical cancer diagnosis.

The rising incidences of cervical cancer globally, especially in developing regions, are increasing the demand for diagnostics. As per the American Cancer Society, in 2024, 13,820 new cases of invasive cervical cancer will be diagnosed in the U.S. Several governments are also launching initiatives and healthcare campaigns to promote cervical cancer screening and prevention.

In September 2023, scientists at the International Agency for Research on Cancer (IARC) and its partners launched the EASTER project, aimed at validating new technologies for cervical cancer screening and diagnosis. The launch of such projects to develop new technologies for cervical cancer diagnosis will provide impetus for the market development.

The cervical cancer diagnostics industry is bifurcated into diagnostic method, age group, end-use, and region.

Based on diagnostic method, the market value from the HPV DNA tests is anticipated to rise at 5.6% CAGR up to 2032, due to the high adoption for cervical cancer diagnosis. These tests offer high sensitivity and specificity in detecting human papillomavirus (HPV) infections, a leading cause of cervical cancer. HPV DNA tests also enable early detection and intervention for improved patient outcomes, further driving increasing utilization in cervical cancer screening programs worldwide.

In terms of end-use, the diagnostic imaging centers segment is estimated to accumulate sizeable share of the cervical cancer diagnostics market, depicting 4.9% CAGR from 2024 to2032. This is owing to the increasing awareness about the importance of regular cervical cancer screening. Of late, there has been high availability of advanced diagnostic imaging technologies in dedicated centers. These centers provide specialized services for cervical cancer detection for offering accurate and timely diagnosis through techniques such as colposcopy, MRI, and ultrasound, contributing to improved patient outcomes.

Regionally, the Asia Pacific cervical cancer diagnostics market size will depict 5.6% growth rate from 2024 to 2032, owing to the rising healthcare expenditure, increasing awareness campaigns, and rollout of government initiatives to improve women health. Rapid advancements in healthcare infrastructure in emerging economies like China and India, along with the growing adoption of screening programs will fuel the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cervical cancer globally
    • 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
    • 3.2.1.3 Rising incidence of HPV Infections
    • 3.2.1.4 Advancements in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited access to healthcare services
    • 3.2.2.2 Social stigma and cultural barriers
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Diagnostic Methods, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pap smear tests
• 5.3 HPV DNA tests
• 5.4 Colposcopy
• 5.5 Biopsy and endocervical curettage
• 5.6 Other diagnostic methods

Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 20-40 years
• 6.3 Above 40 years

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Diagnostic imaging centers
• 7.5 Cancer research institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Arbor Vita Corporation
• 9.3 Becton, Dickinson and Company (BD)
• 9.4 Danaher Corporation
• 9.5 F. Hoffmann-La Roche Ltd
• 9.6 Fujirebio Diagnostics, Inc.
• 9.7 Hologic, Inc.
• 9.8 QIAGEN
• 9.9 Seegene Inc
• 9.10 Thermo Fisher Scientific Inc.